Mithril Medicine
Mithril Medicine is a biotechnology company based in Cambridge, Massachusetts, developing multispecific antibodies for patients with rare genetic diseases.
Contents7 sections
Key facts
July 2025Founder and Early Research
Harvard Business School’s 2025–2026 Blavatnik Fellows announcement identified Cody Tranbarger as Mithril Medicine’s founder and acting CEO, developing antibody therapies for genetic diseases. He completed the biotechnology MS/MBA program in 2025 and was an entrepreneur-in-residence at Atlas Venture, following roles at Prime Medicine and Casdin Capital.[1]
March 2026Founder Selected as Termeer Fellow
The Termeer Institute selected Tranbarger among 17 first-time life-sciences CEOs in its 2026 fellowship, identifying him as Mithril Medicine’s founder and CEO. The program provides leadership development, coaching, mentoring and professional networks for early-stage company leaders.[2]
The institute’s biography described Mithril as a seed-stage developer of antibody therapies for rare genetic disorders. Tranbarger also served with Cure Rare Disease and Accelerating Breakthroughs in EB, connecting his company-building and investment experience with rare-disease research support.[3]
July 2026Acquired by Anthropic
AnthropicAnthropicAnthropic is an artificial intelligence research and product company founded in 2021 that develops the Claude models, assistant, and tools such as Claude Code, and operates as a public benefit corporation. Dario Amodei and Daniela Amodei are its co-founders, and its research covers model safety, interpretability, and steerability.Open the full entry acquired Mithril in July. Tranbarger joined to continue its programs and help lead internal drug development.[4]
October 26, 2026Bridging-Antibody Study
The LAMA2-CMD study examined antibodies bridging laminin-α4 and β-dystroglycan. A tetravalent construct was associated with doubled force and grip strength in diseased mice.[5]
October 26, 2026Evidence Limitations
The unreviewed report used a small, nonrandomized mouse study without a safety assessment. These preclinical findings do not establish human efficacy.[5]
October 27, 2026Lean Research Organization
The founder described one full-time employee coordinating consultants, contract laboratories and Claude to reach in-vivo proof of concept in under 18 months. He called the model “Pipeline-in-a-Person”; specialist and experimental work still involved external teams.[4]
Sources
- Harvard Business School Announces Its 2025-2026 Blavatnik Fellows (opens in a new window)
- Termeer Institute Announces Class of 2026 Termeer Fellows (opens in a new window)
- Termeer Fellows Program (opens in a new window)
- Thrilled to announce that, in July, Mithril Medicine was acquired by Anthropic. (opens in a new window)
- Preclinical Characterization of a Bispecific Bridging Antibody for the Treatment of LAMA2-Related Congenital Muscular Dystrophy (opens in a new window)